AU6198801A - Apoptotic entities for use in treatment of endothelium dysfunction disorders - Google Patents

Apoptotic entities for use in treatment of endothelium dysfunction disorders

Info

Publication number
AU6198801A
AU6198801A AU61988/01A AU6198801A AU6198801A AU 6198801 A AU6198801 A AU 6198801A AU 61988/01 A AU61988/01 A AU 61988/01A AU 6198801 A AU6198801 A AU 6198801A AU 6198801 A AU6198801 A AU 6198801A
Authority
AU
Australia
Prior art keywords
treatment
dysfunction disorders
endothelium dysfunction
apoptotic
entities
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU61988/01A
Other languages
English (en)
Inventor
Anthony E. Bolton
Arkady Mandel
Daniel Sauder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasogen Ireland Ltd
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Publication of AU6198801A publication Critical patent/AU6198801A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU61988/01A 2000-05-25 2001-05-25 Apoptotic entities for use in treatment of endothelium dysfunction disorders Abandoned AU6198801A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2309417 2000-05-25
CA 2309417 CA2309417A1 (en) 2000-05-25 2000-05-25 Apoptotic entities for use in treatment of endothelium dysfunction disorders
PCT/CA2001/000760 WO2001089538A2 (en) 2000-05-25 2001-05-25 Apoptotic entities for use in treatment of endothelium dysfunction disorders

Publications (1)

Publication Number Publication Date
AU6198801A true AU6198801A (en) 2001-12-03

Family

ID=4166242

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61988/01A Abandoned AU6198801A (en) 2000-05-25 2001-05-25 Apoptotic entities for use in treatment of endothelium dysfunction disorders

Country Status (6)

Country Link
US (2) US7279156B2 (enExample)
EP (1) EP1289536A2 (enExample)
JP (1) JP2005508829A (enExample)
AU (1) AU6198801A (enExample)
CA (1) CA2309417A1 (enExample)
WO (1) WO2001089538A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309424A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2309518A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
CA2309417A1 (en) * 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
US20030211548A1 (en) * 2002-01-29 2003-11-13 Oncolmmunin, Inc. Visualization and quantitiation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers
AU2017312194A1 (en) * 2016-08-19 2019-04-04 Immunores-Therapeutics, LLC Gas treatment delivery systems and methods
US20210393990A1 (en) * 2020-06-17 2021-12-23 Donald Murrill BOTTA, JR. Ultrasound therapy for systemic immune modulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696092B2 (en) * 1992-02-07 2004-02-24 Vasogen Ireland Limited Endothelial lining effects and treatment of vasospastic disorders
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
WO1993015778A1 (en) * 1992-02-07 1993-08-19 Anthony Ernest Bolton Method of inhibiting the aggregation of blood platelets
ATE246929T1 (de) 1995-05-05 2003-08-15 Vasogen Ireland Ltd Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen
EP1078043A1 (en) 1998-05-11 2001-02-28 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale New apoptotic bodies, monocyte derived cells containing the same, a process for their preparation and their uses as vaccines
JP2002529510A (ja) * 1998-11-13 2002-09-10 バソジェン アイルランド リミテッド 哺乳動物においてアテローム性動脈硬化症を予防および退行させるための方法
CA2269364A1 (en) 1999-04-19 2000-10-19 Vasogen Ireland Limited Treatment of inflammatory and allergic disorders
CA2271190A1 (en) * 1999-05-06 2000-11-06 Vasogen Ireland Limited Improved method for treating mammals with modified mammalian blood
CA2309417A1 (en) * 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
US7122208B2 (en) * 2001-04-06 2006-10-17 Vasogen Ireland Limited Compositions containing apoptotic entities
US7255880B2 (en) * 2003-04-03 2007-08-14 Vasogen Ireland Limited Treatment of endothelin-related disorders

Also Published As

Publication number Publication date
US20080063631A1 (en) 2008-03-13
US20020058023A1 (en) 2002-05-16
EP1289536A2 (en) 2003-03-12
CA2309417A1 (en) 2001-11-25
WO2001089538A3 (en) 2002-08-01
JP2005508829A (ja) 2005-04-07
WO2001089538A2 (en) 2001-11-29
US7279156B2 (en) 2007-10-09

Similar Documents

Publication Publication Date Title
GB0007193D0 (en) Treatment of movrmrnt disorders
HUP0401023A3 (en) Use of flibanserin in the treatment of sexual disorders
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
WO2002000209A3 (en) Gabapentin analogues for sleep disorders
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
AU2002237667A1 (en) Methods for the treatment and prevention of urinary stone disease
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
AU2001274649A1 (en) Topical preparation of alprostadil for the treatment of erectile dysfunction
AU2002215047A1 (en) Isoquinoline derivatives useful in the treatment of cns disorders
AU2001251306A1 (en) Treatment of sleep disorders with hypocretin-1
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU6198801A (en) Apoptotic entities for use in treatment of endothelium dysfunction disorders
AU2001239510A1 (en) Treatment of renal disorders
HUP0303178A3 (en) Methods and compositions for reducing the taste of pharmaceutically active agents
AU2002226060A1 (en) Compositions containing gangliosides for use in the treatment of skin disorders
PL362980A1 (en) Treatment of sexual dysfunction
HK1055081A (en) Apoptotic entities for use in treatment of endothelium dysfunction disorders
AU8906201A (en) Methods and compositions for the treatment and prevention of sexual dysfunction
AU2002210763A1 (en) Use of 1-ebio in the treatment of bipolar disorders
IL152782A0 (en) S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
EP1315499A4 (en) COMPOSITIONS AND METHODS OF TREATING ANORCAL DISEASES
AU2001274446A1 (en) Vip-related peptides for the treatment of skin disorders
HK1055908A (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase